Key clinical point: Singleton pregnant women with psoriatic arthritis (PsA) had a significantly higher risk for preeclampsia than matched control pregnant women without PsA.
Major finding: Compared with control women, the risk for preeclampsia was much higher in women with PsA (adjusted odds ratio [ aOR] 1.85; 95% CI 1.10-3.12), with the risk being primarily driven by the receipt of monotherapy for PsA before pregnancy (aOR 2.72; 95% CI 1.44-5.13).
Study details: Findings are from an analysis of a register-based cohort study including singleton pregnant women with rheumatoid arthritis (n = 1739), axial spondyloarthritis (n = 819), and PsA (n = 489) who were matched with 17,390, 8190, and 4890 control pregnant women, respectively.
Disclosures: This study was supported by NordForsk and other sources. Some authors declared serving on speakers’ bureaus, receiving research grants, or receiving consulting fees from several sources.
Source: Secher AEP et al. Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: A collaborative matched cohort study from Sweden and Denmark. RMD Open. 2022;8:e002445 (Nov 3). Doi: 10.1136/rmdopen-2022-002445